Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs AVAGE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.
Allergic rhinitis,Nasal congestion
FDA-approved for the topical treatment of stable plaque psoriasis (up to 20% body surface area),FDA-approved for the topical treatment of mild to moderate acne vulgaris,Off-label: treatment of photoaging, facial wrinkles, and certain hyperpigmentation disorders
Adults: 100 mg orally twice daily.
Applied topically as a cream 0.05% to affected areas once daily at bedtime.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Not available; components may be metabolized via hepatic CYP enzymes.
Tazarotene is rapidly metabolized via ester hydrolysis to its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized via oxidation and conjugation (glucuronidation). The enzymes involved include esterases and possibly CYP450 isoforms; specific CYP450 enzymes are not well characterized.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Primarily renal excretion (70-80% as unchanged drug) with 10-20% biliary/fecal elimination.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Approximately 90% bound to albumin and alpha-1-acid glycoprotein.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Oral: 60-70% due to first-pass metabolism; Intravenous: 100%.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No specific dose adjustment required for renal impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
No specific dose adjustment required for hepatic impairment.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
No specific dose adjustment required; however, use with caution due to potential increased sensitivity and skin fragility in elderly patients.
None
Avage is contraindicated in women who are or may become pregnant. Tazarotene is a teratogen, and fetal harm can occur when administered to a pregnant woman. If the drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Avoid contact with eyes, mouth, and mucous membranes,Not for use on eczematous or sunburned skin,May cause severe local skin reactions (e.g., redness, peeling, burning, stinging),Photosensitivity: patients should avoid or minimize exposure to sunlight and artificial UV sources,Concomitant use with other photosensitizing agents should be approached with caution
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
Pregnancy (FDA Pregnancy Category X),Women of childbearing potential unless using effective contraception and have a negative pregnancy test within 2 weeks prior to therapy,Hypersensitivity to tazarotene or any component of the formulation
No known food interactions with topical naftifine. No dietary restrictions required.
AVAGE should be taken with a meal containing fat (e.g., whole milk, peanut butter) to enhance absorption. Avoid excessive vitamin A supplements as they may add to toxic effects. Grapefruit juice may increase isotretinoin levels; consider avoidance.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Avoid use throughout pregnancy.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
Contraindicated in breastfeeding. Excreted into human milk; M/P ratio not established. Risk of serious adverse effects in nursing infant, including keratoderma-like skin changes and potential for growth impairment.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No dose adjustment applicable; drug is absolutely contraindicated in pregnancy due to teratogenicity. No data on pharmacokinetic changes; theoretical increased clearance due to expanded plasma volume may occur but is clinically irrelevant given contraindication.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
AVAGE (isotretinoin) is highly teratogenic; confirm negative pregnancy test within 5 days before starting therapy and monthly thereafter. Monitor triglycerides, liver function, and CBC at baseline and monthly. Avoid blood donation during treatment and for 1 month after discontinuation. Use with caution in patients with depression; monitor for mood changes. Administer with food to increase absorption.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
AVAGE can cause severe birth defects; females must use two effective forms of contraception and have monthly pregnancy tests.,Do not donate blood while taking AVAGE and for 1 month after stopping.,Avoid exposure to sunlight or tanning beds; use sunscreen and protective clothing.,Report any signs of depression, mood changes, or thoughts of self-harm immediately.,Take each dose with a full meal to ensure proper absorption.,May cause dry skin, lips, eyes; use moisturizers and artificial tears as needed.,Avoid waxing or laser treatments during therapy and for 6 months after.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs AVAGE, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. AVAGE is a Topical Retinoid that works by Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and AVAGE depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of AVAGE is: Applied topically as a cream 0.05% to affected areas once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and AVAGE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. AVAGE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.